The Danish pharmaceutical giant raised its full-year guidance to reflect better pricing in the U.S. and as global demand for its weight-loss and diabetes drugs continued to outstrip supply.
The Danish pharmaceutical giant raised its full-year guidance to reflect better pricing in the U.S. and as global demand for its weight-loss and diabetes drugs continued to outstrip supply.